利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

97 条记录 (耗时 0.057 秒)

    COMPOSITIONS AND METHODS FOR INHIBITING VIRAL REPLICATION
    42.
    发明申请
    COMPOSITIONS AND METHODS FOR INHIBITING VIRAL REPLICATION 有权
    用于抑制病毒复制的组合物和方法

    公开(公告)号：US20080194512A1

    公开(公告)日：2008-08-14

    申请号：US11959936

    申请日：2007-12-19

    申请人： Matthias John ,  Stefan Limmer ,  Hans-Peter Vornlocher ,  Roland Kreutzer

    发明人： Matthias John ,  Stefan Limmer ,  Hans-Peter Vornlocher ,  Roland Kreutzer

    IPC分类号： A61K31/70 ,  C07H21/04

    CPC分类号： C12N15/1131 ,  C12N2310/14 ,  C12N2310/53

    摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.

    摘要翻译： 本发明涉及具有长度小于30个核苷酸的核苷酸序列的双链核糖核酸（dsRNA），并且其基本上与3'非翻译区（3'-UTR）的至少一部分相同 （+）链RNA病毒，例如HCV，以及包含dsRNA的药物组合物，以及药学上可接受的载体。 药物组合物可用于治疗由（+）链RNA病毒的复制或活性引起的感染和疾病以及用于抑制病毒复制的方法。

    Compositions and methods for inhibiting viral replication
    44.
    发明授权
    Compositions and methods for inhibiting viral replication 有权
    用于抑制病毒复制的组合物和方法

    公开(公告)号：US07348314B2

    公开(公告)日：2008-03-25

    申请号：US10384512

    申请日：2003-03-07

    申请人： Matthias John ,  Stefan Limmer ,  Hans-Peter Vornlocher ,  Roland Kreutzer

    发明人： Matthias John ,  Stefan Limmer ,  Hans-Peter Vornlocher ,  Roland Kreutzer

    IPC分类号： A61K31/70 ,  C07H21/04 ,  C07H21/00

    CPC分类号： C12N15/1131 ,  C12N2310/14 ,  C12N2310/53

    摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.

    摘要翻译： 本发明涉及具有长度小于30个核苷酸的核苷酸序列的双链核糖核酸（dsRNA），并且其基本上与3'非翻译区（3'-UTR）的至少一部分相同 （+）链RNA病毒，例如HCV，以及包含dsRNA的药物组合物，以及药学上可接受的载体。 药物组合物可用于治疗由（+）链RNA病毒的复制或活性引起的感染和疾病以及用于抑制病毒复制的方法。

    RNAi Modulation of AHA and Therapeutic Uses Thereof
    45.
    发明申请
    RNAi Modulation of AHA and Therapeutic Uses Thereof 审中-公开
    AHA的RNAi调节及其治疗用途

    公开(公告)号：US20120142757A1

    公开(公告)日：2012-06-07

    申请号：US13343426

    申请日：2012-01-04

    申请人： Rainer Constien ,  Birgit Bramlage ,  Pamela Tan ,  Hans-Peter Vornlocher ,  William Balch

    发明人： Rainer Constien ,  Birgit Bramlage ,  Pamela Tan ,  Hans-Peter Vornlocher ,  William Balch

    IPC分类号： A61K31/713 ,  A61P35/00 ,  C12N15/63 ,  C12N5/10 ,  C12N5/02 ,  C12N15/113 ,  A61P11/00

    CPC分类号： C12N15/113 ,  C12N2310/14 ,  C12N2310/3515

    摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.

    摘要翻译： 本发明涉及用于抑制Aha基因（Aha1基因）表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸 并且其与Aha基因的至少一部分基本上互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于治疗由Aha1表达引起的疾病和使用该药物组合物表达Aha基因的方法; 以及抑制细胞中Aha基因表达的方法。